US Bancorp’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

US Bancorp’s Portfolio PSTX Stock Details PSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-26	Closed	-$250	–	4417
2024 Q4	$250	Buy	+26	New	+$136	﹤0.01%	4064
2024 Q3	–	Sell	-5,200	Closed	-$15.2K	–	4205
2024 Q2	$15.2K	Hold	5,200	–	–	﹤0.01%	3167
2024 Q1	$16.6K	Buy	+5,200	New	+$17.3K	﹤0.01%	3166

Other funds holding PSTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

US Bancorp's PSTX Position: Q1 2025 in Review

US Bancorp sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 26 shares — an estimated $250 sold.

US Bancorp first reported a position in PSTX in Q1 2024 and held it in 3 quarters. The position peaked at $16.6K in Q1 2024. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.

US Bancorp reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
US Bancorp sold 26 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $250.
US Bancorp first reported a position in Poseida Therapeutics, Inc. Common Stock in Q1 2024 and held it in 3 quarters.
US Bancorp's Poseida Therapeutics, Inc. Common Stock position peaked at $16.6K in Q1 2024.
1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.

Based on US Bancorp's 13F filing for Q1 2025, filed 8 May 2025.